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Abstract:	  
	  i.  The aim of this study was to determine if methicillin-resistant Staphylococcus aureus 
(MRSA) strains could be identified in the milk of dairy cattle in a Paso Del Norte region 
dairy. Using physiological and PCR-based identification schemes, 40 S. aureus strains 
were isolated from 133 milk samples analyzed. This investigation also included the 
production of draft genome sequences of a MRSA and a methicillin-susceptible isolate.  
Genomic analysis of these strains demonstrate that strains H29 and PB32 represent novel 
clones of sequenced human and/or bovine-related strains of S. aureus. 
ii.  The draft genomes of a heterogeneous vancomycin-intermediate resistant 
Staphylococcus aureus (VISA) strain MM66 and strain MM66RVI-4 expressing reduced 
vancomycin-intermediate resistance harbored the same mutation in graS of a two-
component regulatory system. MM66RVI-4 has also lost staphylococcal cassette 
chromosome, SCCmec, corroborating methicillin-resistance in this strain and harbored 
mutations present in vraG, encoding an ATP-binding cassette transporter. The observed 
genetic alterations in both strains have been shown to affect vancomycin resistance levels 
in VISA.  
iii.  Elizabethkingia species are environmental isolates that exhibit a multidrug-resistance 
phenotype and are a cause of life-threatening infections in immunocompromised 
individuals. To date, most studies have focused on the clinical aspects of this organism, 
and little is known regarding its antimicrobial resistance mechanisms. In addition, the 
phylogenetics and speciation of this genus is still highly controversial and has yet to be 
thoroughly defined.  In an effort to clear up confusion surrounding the speciation of this 
genus as well as identifying possible antimicrobial resistance mechanisms, we report the 
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1.1 Methicillin-resistant Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive pathogen that is responsible for 
infections in both the hospital setting as well as in the community.  S. aureus causes a 
wide array of infections ranging from moderate skin infections to more life-threatening 
infections such as endocarditis. In the early 1940s the β-lactam antibiotic penicillin was 
first made commercially available to treat S. aureus infections. Today, greater than 80% 
of S. aureus isolates are resistant to penicillin (113). The emergence of penicillin 
resistance led to introduction of the semi-synthetic penicillin, methicillin.  However, in 
1961, methicillin-resistant S. aureus (MRSA) were reported (83). The MRSA phenotype 
results from the acquisition of a mobile genetic element known as the staphylococcal 
cassette chromosome mec (SCCmec) (65, 78).  To date, 11 different SCCmec types have 
been described and range from 21 kb to 58 kb in size (http://www.sccmec.org/).  SCCmec 
is comprised of a mec region containing the mecA gene (encodes an alternative penicillin 
binding protein PBP2a), mec regulatory genes mecR1 and mecI, two cassette
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chromosome recombinase genes (ccr) responsible for site-specific integration/excision from 
the chromosome and a “junkyard” region consisting of variable genes (79).   
S. aureus isolates demonstrate resistance to the majority of antimicrobials used to 
treat infections. S. aureus was reported to colonize the nasal nares of ~28% of the U.S. 
population in 2004 (54) and if it contaminates a normally sterile site, it can cause infection. It 
was estimated that in 2011, there were 80,461 invasive MRSA infections in the U.S. of 
which resulted in 11,285 deaths (33). Risk factors for hospital-acquired MRSA infections 
include MRSA colonization, prolonged or history of hospitalization, long-term care residence 
and history of surgery (94).  
Several molecular typing techniques are used to determine the spread of specific S. 
aureus strains, which include multi-locus sequence typing (MLST) and pulsed-field gel 
electrophoresis (PFGE).  MLST uses sequencing of 7 housekeeping gene amplicons to group 
MRSA strains into clonal complexes (CC) using “based upon related sequence types” 
(BURST) analysis (43).  The majority of S. aureus strains isolated worldwide belong to a 
handful of CCs that include CC1, CC5, CC8, CC9, CC15, CC22, CC25, CC30, CC45, and 
CC51 (37, 143) with the rest belonging to smaller, less common clonal complexes.  To date, 
the largest clonal complex described is CC8 represented by 248 strains of both hospital-
acquired and community-acquired human isolates as well as animal isolates 
(http://saureus.mlst.net/).  PFGE is a method that uses specific infrequent cutting restriction 
endonuclease enzymes (eg. SmaI) to cleave genomic DNA into different sized fragments that 
give distinct banding patterns for specific strains.  This allows for the capability of 
determining the possible gain or loss of mobile genetic elements and/or mutations via the 
introduction or removal of restriction enzyme sites as determined by the number of bands 
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seen on an agarose gel (183).  Based on this method, the majority of S. aureus clones in the 
U.S. are from twelve lineages, PFGE types USA100 – USA1200, which are representative of 
hospital-acquired and community-acquired S. aureus strains (126).   
S. aureus is also a pathogen of swine, horses, cattle and domestic animals.  S. aureus 
is the major cause of bovine mastitis (infection within the mammary gland), infecting 
between 7% and 40% of all dairy cows in the United States (119). Bovine mastitis from 
MRSA was first reported in 1972 and MRSA transmission appears to occur between animals, 
and from animals to humans (39, 102, 114, 193). S. aureus mastitis causes scarring and 
fibrosis of the mammary gland along with excretion of pus, thereby reducing the volume and 
quality of the milk produced by the animal (12).  In addition to the burden of reduced milk 
production, the difficulty of treating S. aureus infections means that the primary strategy for 
dealing with an infected animal is quarantine with antibiotic treatment, and in the case of 
treatment failure, the animal will be culled (162). The economic impact of bovine mastitis S. 
aureus infections is also difficult to estimate (~$2 billion in the US (192)) with losses coming 
from reduced milk yield, replacement of culled animals, additional labor, and veterinary and 
antibiotic costs (164). Carriage of MRSA by livestock has been shown to correlate with the 
MRSA colonization of farmers and farm families, veterinarians and healthcare workers (85, 
193, 202). There is also concern about the potential of MRSA to be transmitted to humans 
through contaminated food products although what risk is actually posed remains a matter of 
debate (20, 35, 95).  MLST analyses have shown that livestock-associated MRSA belong to a 
small number of CC with the most prevalent being CC398 and it is known that CC398 strains 
also cause infections in humans (115, 160, 193).  A recent report suggests that CC398 strains 
emerged from a human evolved methicillin-susceptible S. aureus (MSSA) strain and that 
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livestock-associated MRSA sublineages arose during antimicrobial selection in livestock 
(152). 
1.2 Vancomycin  
 The evolution of methicillin resistance led to the pursuit of alternative treatments for 
MRSA infections (43). In 1958, the glycopeptide antibiotic vancomycin was first used 
clinically to fight infections caused by Gram-positive bacteria (103). Vancomycin, a 
bactericidal drug, binds to the D-alanyl-D-alanine residues in growing peptidoglycan chains, 
preventing the cross-linking of these chains and thus inhibiting peptidoglycan synthesis.  
Vancomycin is currently the antibiotic of choice for treating serious MRSA infections in the 
United States (103, 111). 
1.3 Vancomycin-intermediate resistant Staphylococcus aureus  
In 1997, the first vancomycin-intermediate resistant S. aureus (VISA) strain was 
reported in Japan exhibiting a vancomycin minimum inhibitory concentration (MIC) of 8 
µg/ml and since then, many more have been described globally (66).  Heterogeneous 
vancomycin-intermediate resistant S. aureus (hVISA) are strains that demonstrate a 
vancomycin MIC within the susceptible range (MIC ≤ 2 µg/ml) but have a subpopulation of 
cells within the vancomycin-intermediate range (MIC = 4 - 8 µg/ml) that are not detected by 
standard broth and disk diffusion techniques.  In 1996, Mu3 was the first hVISA strain 
described in Japan from a patient with unsuccessful vancomycin treatment (64). Mu3 
exhibits a vancomycin MIC of 3 µg/ml with a subset of cells that demonstrate vancomycin-
resistance up to 9 µg/ml vancomycin. In 2002, the first vancomycin-resistant S. aureus 
(VRSA, MIC ≥ 32 µg/ml) strain was isolated in the U.S. (23, 25).  VRSA strains have been 
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shown to carry van genes acquired from vancomycin-resistant enterococci that exhibit high-
level vancomycin resistance (197).  The VISA mechanism in S. aureus differs from the van-
mediated resistance mechanism of VRSA. Several phenotypic changes exhibited by 
hVISA/VISA strains have been described, which include reduced autolysis, thicker cell 
walls, reduced peptidoglycan cross-linking and overexpression of PBP2 and PBP2a (14, 15, 
30, 31, 34, 47, 62, 71, 86, 96, 118, 133, 146, 155, 171, 172). Comparative genomic studies 
have identified several genetic changes associated with the hVISA/VISA phenotype, 
however, the exact mechanisms of resistance are still poorly understood. The mechanism 
behind vancomycin-intermediate resistance are sequential mutations (or a single mutation) 
that fully or partially changes the function of a specific gene(s) (73).  Mutations in genes 
associated with the hVISA/VISA phenotype include rpoB, walKR, vraSR, graRS, agr, yycH, 
yvqF, isdE (29, 50, 74, 81, 90, 121, 136, 142, 168, 205). Mutations in regulatory genes 
involved in cell wall metabolism such as vraSR, graRS and walKR have most frequently been 
associated with the VISA phenotype, however, the exact mutations found within these genes 
can differ between S. aureus strains (32, 70, 72, 74, 89, 136, 137).  Therefore, based on the 
reported VISA descriptions to date, the VISA phenotype can result from multiple mutations 
and/or mutation combinations. 
1.4 Staphylococcus aureus genomics 
The first S. aureus genomes were sequenced in 2001, which were MRSA strain N315 
and VISA strain Mu50 (99).  Sequencing of these genomes revealed that the majority of the 
antibiotic and virulence genes of S. aureus reside on mobile genetic elements, i.e. plasmids, 
bacteriophages, and pathogenicity islands (99).  S. aureus genomes are ~2.8 to 2.9 Mbp in 
size and have similar chromosomal synteny. The majority of the genome (~75%), known as 
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the “core genome,” is comprised of essential genes that encode proteins needed for cell 
growth, cellular metabolism and replication (110).  The other ~25% of the S. aureus genome 
is considered the “accessory genome” which contains mobile genetic elements such as 
plasmids and bacteriophages that can be transferred between strains (110).  As of March 
2014, a total of 50 S. aureus genomes have been completely sequenced with another 2,710 
genomes in the draft genome state. Sequencing of whole genomes allows for the comparison 
of genetic differences between organisms down to single nucleotide changes.  Several studies 
have used comparative genomics of closely related S. aureus strains, such as a parent strain 
compared to the antimicrobial-resistant strain, to determine what mutations, if any, may be 
responsible for the variations in susceptibilities.  For example, Mwangi et al. was able to use 
whole-genome sequencing to track the development of genetic mutations of a S. aureus strain 
originally isolated as MRSA, and after undergoing vancomycin therapy, evolving to VISA 
(136).  The first S. aureus strain sequenced (JH1) was susceptible to vancomycin and was 
isolated prior to vancomycin treatment. After the start of vancomycin treatment, a second S. 
aureus strain (JH9) was isolated and exhibited a VISA phenotype. This method identified 35 
mutations between the two S. aureus genomes that contributed to both the multidrug-resistant 
and VISA phenotype of JH9 (136).  In another study, Neoh et al. used comparative genomics 
of two closely related hVISA/VISA strains (Mu3/Mu50) to determine which mutations 
contribute to their hVISA/VISA phenotype (137).  In this study, 16 mutations were found 
between the Mu3 and Mu50 genomes including a mutation in graR, the response regulator of 
a two-component regulatory system, which shown to convert the hVISA strain Mu3 into a 
full VISA strain, similar to that of Mu50 (137). As a whole, these studies demonstrate the 
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ability of using whole-genome sequencing as a means to ascertain the genetic basis of 
antibiotic resistance of S. aureus.  
1.5 Elizabethkingia species 
The genus Elizabethkingia (formerly Chryseobacterium and Flavobacterium) belongs 
to the phylum Bacteroidetes, within the Flavobacteriaceae family.  Currently, the genus 
consists of three species, E. meningoseptica, E. miricola and E. anophelis, with the latter 
being the most recent addition.  E. meningoseptica was isolated in 1958 from a case of 
neonatal meningitis (17, 92), E. miricola from condensation water in the space station Mir in 
2003 (105), and E. anophelis from the midgut of the mosquito, Anopheles gambiae, in 2011 
(87).   
Elizabethkingia species are Gram-negative, non-motile, non-spore-forming rods (17, 
87, 91, 105). Colonies are circular, translucent, smooth, off-white in color and range from 1 
µm to 2 µm in size (17, 87, 91, 105).  Optimal growth is seen at 25 - 37°C but not at 5 or 
42°C and growth on MacConkey agar is variable (17, 87, 91, 105). All species are oxidase, 
catalase, and indole positive.  Acid is produced from glucose, lactose, mannitol, maltose and 
trehalose (17, 87, 91, 105).  Acid is not produced from arabinose, xylose, adonitol, dulcitol, 
raffinose, and salicin (17, 87, 91, 105). Acid production from rhamnose, sucrose, and 
cellobiose is seen for E. anophelis, however no acid production is seen for E. meningoseptica 
and E. miricola (17, 87, 92, 105). Aesculin hydrolysis is positive and starch hydrolysis is 
negative for all three species, however urea hydrolysis is negative for E. meningoseptica and 
E. anophelis and positive for E. miricola (17, 87, 92, 105).  H2S production is positive for E. 
miricola and negative for E. meningoseptica and E. anophelis (17, 87, 92, 105). 
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1.6 Clinical aspects of Elizabethkingia species  
Elizabethkingia are opportunistic pathogens that have been found to be the cause of 
many different types of infections in both adults and children.  Infections are mainly found in 
neonates and immunocompromised adults.  The majority of infections reported are 
presumably caused by E. meningoseptica, however, due to difficulties in speciation of the 
members of this genus, the exact organism causing the infection is most likely unknown.  
Infections reportedly caused by E. meningoseptica include meningitis (17, 92), sepsis (176), 
endocarditis (13), pneumonia (106), bacteremia (107), cellulitis (176), sinusitis (174), 
endophthalmitis (45), septic arthritis (97), peritonitis (145), keratitis (2), osteomyelitis (101), 
pericarditis (112), pyoventriculitis (187) and necrotizing fasciitis (100).  Several different 
antibiotic therapies have been used in the treatment of infections caused by putative E. 
meningoseptica that include ciprofloxacin, levofloxacin, gentamicin, vancomycin, rifampin, 
piperacillin/tazobactam and linezolid (4, 24, 59, 60, 75).  However, most infections are 
unsuccessfully treated with the above therapies due to a multidrug-resistant (MDR) 
phenotype exhibited by E. meningoseptica.  To date, there has been only one report of an 
infection caused by E. miricola and in that case it was originally misidentified as E. 
meningoseptica (55).   In 2013, the first case of infection caused by E. anophelis was 
reported in Africa and identified through the utilization of 16S rRNA gene sequence 
comparisons of type strains within the Chryseobacterium, Bergeyella, Riemerella, 
Empedobacter and Elizabethkingia genera (48).  Soon after the initial description of the first 
E. anophelis infection, additional infections were reported in Singapore.  These strains were 
originally thought to be E. meningoseptica on the basis of matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry (MALDI-TOF) (184).  However, whole genome 
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alignments and 16S rRNA gene sequencing demonstrated that the isolates were more closely 
related to E. anophelis than E. meningoseptica (184). 
 Elizabethkingia infections in humans have been linked to a wide variety of sources 
that include contaminated sinks (21, 68), pasteurizers (31), aerosolizers (167), garden hoses 
(167), humidifiers (174), chlorhexidine gluconate solution (28) and povidone iodine prep 
pads.  It has also been found in the pharynx, nose and throat of healthy babies, suggesting the 
ability of humans to be asymptomatic carriers of Elizabethkingia (165, 186, 195).  In addition 
to clinical sources, Elizabethkingia have been isolated from a variety of other environmental 
niches that include soil (188), water (188) and spent nuclear fuel pools (26). 
 Elizabethkingia are not only human pathogens but also have been isolated from many 
different species of diseased animals. The first documented case in an animal was in 1974 
from meningitis in a cat (173).  Since then, many more infections have been documented in 
animals including different species of frogs, freshwater fish, snakes, turtles, birds and dogs 
(52, 56, 80, 124, 128, 203).  Elizabethkingia have also been isolated from several different 
species of insects that include the fowl tick Argas persicus and mosquitoes species Aedes 
aegypti, Anopheles gambiae, Anopheles stephensi and Anopheles sinensis (41, 104, 108, 131, 
154, 185).	  
1.7 Speciation of Elizabethkingia species 
Since the initial isolation of E. meningoseptica, there have been some uncertainties 
surrounding classification of new Elizabethkingia strains.  Before the popularity/ease of 
whole-genome sequencing, the DNA-DNA hybridization technique was used for defining 
bacterial species. DNA-DNA relatedness of 70% or greater was recommended as the 
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standard in delineating species (196).  Parallel studies by Ursing and Bruun (1987) used 
DNA-DNA hybridization and phenotypic characterization to separate several E. 
meningoseptica strains into two genomic groups (18, 188).  Group I, which included 3 
isolates, demonstrated 90% or greater hybridization to the type strain of E. meningoseptica 
(ATCC 13253T), while group II demonstrated 36-48% hybridization to ATCC 13253T.  
Despite these genetic differences seen with DNA-DNA hybridization, all strains were still 
considered E. meningoseptica in the databases and even in recent publications.   In 1994, six 
Flavobacterium species, including E. meningoseptica, were reclassified into the 
Chryseobacterium genus based upon 16S rRNA similarities (189).  In 2005, phylogenetic 
(16S rRNA) and phenotypic data demonstrated that E. meningoseptica and E. miricola could 
be differentiated from other Chryseobacterium species, therefore transferring these species to 
the new genus Elizabethkingia (91). Additionally, in that same study, DNA-DNA 
hybridizations of several Elizabethkingia strains were confirmed (91). However, in all studies 
to date, the decision to not separate the genetically different E. meningoseptica type strain 
from other Elizabethkingia strains is due to no distinct phenotypic variations or differences 
seen in 16S rRNA sequences among the strains. Today, 16S rRNA sequencing is continually 
being used for the speciation of Elizabethkingia strains despite the inability of this 
methodology to differentiate between the species of this genus.  In an effort to demonstrate 
why 16S rRNA sequence comparison is a poor predictor for speciation of Elizabethkingia, a 
phylogenetic tree was constructed using 59 publicly available Elizabethkingia 16S rRNA 
gene sequences (1287 bp in length).  Figure 1 clearly demonstrates that the species within 
this genus cannot be separated from each other on the basis of 16S rRNA sequence due to the 
fact that all three species within this genus are intermingled.  In addition, the species names 
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already given may be incorrect due to speciation being determined primarily using the 16S 
rRNA sequences.  Genomic differences seen with the DNA-DNA hybridization studies 
demonstrate that the E. meningoseptica type strain is clearly a different species from the 
majority of the other reported E. meningoseptica strains (91, 188). Since there is little, if any, 
discernible phenotypic differences between Elizabethkingia species and 16S rRNA 
sequencing does not effectively discern Elizabethkingia species, this has led us to complete 
and compare the draft genomes of E. meningoseptica and the recently characterized E. 





























Figure 1.  Maximum likelihood tree based on 16S rRNA gene sequences from 
sequenced Elizabethkingia in the NCBI database (http://www.ncbi.nlm.nih.gov/).  
Flavobacterium johnsoniae UW101 was used as an outgroup. Bar represents 
0.02 substitutions per nucleotide position over 1287 bp. 
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 GS-7-08 (E. meningoseptica)
 YB-29 (E. meningoseptica)
 EAPL21 (E. meningoseptica)
 ATCC 51720 (E. meningoseptica)
 CIP 6059 (E. meningoseptica)
 ATCC 13255 (E. meningoseptica)
 ATCC 13254 (E. meningoseptica)
 LMG 12280 (E. meningoseptica)
 CIP 6058 (E. meningoseptica)
 PINT (E. meningoseptica)
 AMA (E. meningoseptica)
 DBP-WUST (E. meningoseptica)
 GEO (E. meningoseptica)
 pp5b (E. meningoseptica)
 HO1J100 (E. meningoseptica)
 AB1572 (E. meningoseptica)
 CIP 7830 (E. meningoseptica)
 GTC 862 (E. miricola type strain)
 R3-4A (E. meningoseptica)
 Che01 (E. meningoseptica)
 1F4 (E. meningoseptica)
 ATCC 33958 (E. miricola)
 CIP 79.5 (E. meningoseptica)
 LDVH 337.01 (E. meningoseptica)
 NTU 870424-IL (E. meningoseptica)
 W2 (E. meningoseptica)
 W1 (E. meningoseptica)
 W3 (E. meningoseptica)
 CS 2-1 (E. meningoseptica)
 LMG 4027 (E. meningoseptica)
 ATCC 13253 (E. meningoseptica type strain)
 D14018 (E. meningoseptica)
 BAB-227 (E. meningoseptica)
 12420 (E. meningoseptica)
 CIP 6057 (E. meningoseptica)
 JL1 (E. meningoseptica)
 L99 (E. miricola)
 M58791 (E. meningoseptica)
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1.8 Goals of these studies 
i.  The purpose of this study was to characterize numerous S. aureus strains isolated from raw 
milk samples collected from mastitic and healthy dairy cattle from a Paso Del Norte region 
dairy. This investigation also included the production of draft genome sequences of a MRSA 
and a MSSA isolate, and the comparison of these draft genomes with S. aureus genomic 
sequences present in the databases. 
ii.  Previously, a clinical hVISA strain, MM66, was isolated from the Memorial Medical 
Center in Las Cruces, New Mexico (38). In an effort to provide more information on the 
nature of the hVISA mechanism in MM66, we have completed the draft genomes of MM66 
and a MM66 isolate (MM66RVI-4) expressing reduced vancomycin-intermediate resistance. 
iii.  Elizabethkingia species are environmental isolates that exhibit a multidrug-resistance 
phenotype and are a cause of life-threatening infections in immunocompromised individuals. 
To date, most studies have focused on the clinical aspects of this organism, and little is 
known regarding its antimicrobial resistance mechanisms. In addition, the phylogenetics and 
speciation of this genus is still highly controversial and has yet to be thoroughly defined.  In 
an effort to clear up confusion surrounding the speciation of this genus as well as identifying 
possible antimicrobial resistance mechanisms, whole genome sequencing of the E. 







MATERIALS AND METHODS 
 
 
2.1 Bacterial storage and preparation of stock plates 
 Stock cultures of S. aureus were maintained on either Mueller Hinton agar 
(MHA), Luria Broth agar (LBA) or Tryptic Soy Agar (TSA) and E. meningoseptica 
ATCC 13253T were maintained on nutrient agar (NA) plates at 4°C.   Single colonies 
were used to initiate growth in 2 ml of liquid media which were grown overnight at 30°C 
(E. meningoseptica) or 37°C (S. aureus strains) in a shaking incubator (200 rpm).  Five 
hundred microliters of overnight cultures were transferred to a cryotube containing 500 
µl of 50% glycerol to reach a final glycerol concentration of 25%.  These glycerol stocks 
were then stored at -20°C and -80°C and were used to streak bacterial isolates onto 
working stock plates.  
2.2 Isolation and characterization of S. aureus dairy strains 
Samples of raw milk were collected from 33 hospital cows, some receiving 
antibiotic treatment, and 100 healthy cows in two milking parlors (A and B) at a local 
dairy.  The isolation of S. aureus strains was carried out as follows.
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Briefly, 100 µl of phosphate buffered diluted milk samples were spread onto Baird-
Parker agar (Becton Dickinson and Co., Sparks, MD) plates and incubated at 37°C for  
48 h. Resulting colonies were then subjected to Gram staining, a catalase test with 3% 
hydrogen peroxide and a coagulase test using rabbit plasma (Becton Dickinson and Co.). 
Presumptive S. aureus isolates were further scrutinized on mannitol salt agar (Acumedia 
Manufacturers, Inc., Lansing, MI) plates. Luria broth (LB) cultures of all presumptive 
isolates were then grown overnight and glycerol (20% v/v) was added to aliquots which 
were then stored at -80°C.  Working cultures of these isolates were maintained on LBA 
plates at 4°C.  Total DNA from 20 ml LB overnight cultures of 40 suspected S. aureus 
milk isolates, two positive control S. aureus lab strains (COL and ATCC 25923) and a 
negative control culture (Staphylococcus epidermidis ATCC 12228), were isolated as 
described below (157). These DNA samples were then scrutinized by a PCR protocol 
designed to detect the S. aureus-specific nucA nuclease gene or for mecA as previously 
described (16, 134). 
2.3 Milk growth curves 
The growth rate of ten S. aureus dairy strains plus one laboratory strain, COL in 
TSB and commercially available milk was compared.  Briefly, overnight cultures were 
diluted in 1 X phosphate buffered saline (PBS) to an OD650nm of 0.01.  Five hundred 
microliters of diluted culture was then added to 50 ml of TSB or milk followed by 
incubation at 37°C with shaking (200 rpm).  Serial dilutions (10-fold) were carried out 
and colony counts (CFU/ml) were determined on TSA plates at time-points 0, 1, 2, 3, 4, 




2.4 Vancomycin-susceptible MM66 mutant isolation 
 Selection of the vancomycin-susceptible MM66 mutant, MM66RVI-4 was done 
using a replica plating method, by Mitchell Nelson (New Mexico State University).  
Briefly, a 5 ml LB culture of MM66 was maintained by passaging a 10% inoculum (final 
v/v) through drug-free LB everyday for 14 days. At days 7 and 14, the cultures were 
serially diluted to 10-6 and 100 µl aliquots of the diluted cultures were pipetted onto an 
LBA plate and spread across the surface using a sterile cotton swab, followed by 
incubation overnight at 37°C.  A Kimwipe (Kimberly-Clark Professional, Dallas, Texas) 
was stretched across a PVC replica plating tool (Bel-art Scienceware, Wayne, NJ) and 
secured with a rubber band.  The inoculated plates were then inverted and pressed onto 
the surface of the Kimwipe with slight pressure.  The resulting imprinted Kimwipe was 
then used to transfer colony imprints onto drug-free LBA plates (control plates) and onto 
plates containing 1 µg/ml vancomycin.  The plates were then examined for vancomycin 
susceptible mutant colonies that grew only on the control plates and not the vancomycin-
containing plates.  Single suspected vancomycin-susceptible mutant colonies were then 
picked off the drug-free plates and used to inoculate 3 ml of drug-free LB and grown 
overnight (37°C, 200 rpm). Inoculums from these overnight cultures were then used to 
create 20% glycerol freezer stocks and stored at -80°C. 
2.5 Extraction of genomic DNA 
 Initially, strains were grown overnight in 25 ml of LB at 37°C (200 rpm) for S. 
aureus strains, 25 ml of nutrient broth (NB) at 30°C (200 rpm) for E. meningoseptica 
ATCC 13253T.  Cells were harvested by centrifugation at 7, 598 x g for 8 min. at 4°C and 
resuspended in 3 ml of lysis solution (20 mM Tris-HCl; 2 mM EDTA; 1.2% Triton X-
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100; pH 8.0).  Lysostaphin was added to the S. aureus isolates to a final concentration of 
10 mg/l and lyzozyme was added to the Elizabethkingia isolates (final concentration of 2 
mg/ml) and samples were incubated at 37°C or 30°C for 2 hr.  After incubation, 0.3 ml of 
a 5% w/v SDS-50% v/v ethanol solution was added and vortexed for 10 s followed by the 
addition of 2 ml of phenol/chloroform/isoamyl alcohol (25:24:1; Sigma Aldrich).  
Samples were centrifuged at 47,488 x g for 10 min at 4°C and the supernatant was 
transferred to a new tube.  The aqueous phase was extracted with an equal volume of 
chloroform (Sigma Aldrich), vortexed and centrifuged at 16,100 x g for 10 min at 4°C.  
The supernatant was then transferred to a new tube and two times the volume of 100% 
ethanol (Pharmco-Aaper, Brookfield, CT) was added and mixed well followed by 
centrifugation at 16,100 x g for 25 min at 4°C to pellet the DNA.  The pellet was 
resuspended in 1 ml of TE buffer and RNAse-A (Sigma Aldrich) was added to a final 
concentration of 20 mg/l.  Samples were incubated overnight at room temperature.  
Following overnight incubation, 0.2 ml of phenol/chloroform/isoamyl alcohol (25:24:1) 
was added, vortexed and centrifuged at 16,100 x g for 10 min at 4°C to get the aqueous 
phase.  An equal amount of chloroform was added to each sample and again centrifuged 
at 16,100 x g for 10 min at 4°C.  The aqueous phase was then transferred to a new tube 
and one times the volume of 3 M sodium acetate and two times the volume of 100% 
ethanol was added.  The samples were centrifuged once again at 16,100 x g for 10 min at 
4°C and the supernatants were decanted.  The samples were allowed to dry at room 
temperature for 10 min then the DNA pellet was dissolved in 30 µl of 1X TE buffer.  The 
purity and integrity of the DNA sample was determined by gel electrophoresis.  Extracted 
DNA was stored at -20°C. 
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2.6 Draft genome sequencing 
The draft genomes of S. aureus H29 and PB32 were sequenced (>20X overall 
coverage) using Roche 454 GS (FLX Titanium) pyrosequencing according to 
manufacturer’s instructions at New Mexico State University (Las Cruces, NM).  All reads 
were assembled into contigs utilizing the Newbler assembler (v 2.3; 454 Life Sciences). 
Draft genomes of S. aureus MM66 and MM66RVI-4 were produced with the Roche 454 
GS (Junior) pyrosequencing platform at Oklahoma State University.  Sequencing of 
MM66 generated 187,437 reads (>30 X coverage; average read length 455.4 bp) while 
MM66RVI-4 generated 213,277 reads (>30 X coverage; average read length 468.58 bp).  
Both genomes were assembled using the Roche GS de novo assembler (v 2.7). Contigs 
from S. aureus genomes were then compared to other genomes in the databases utilizing 
BLASTn (http://blast.ncbi.nlm.nih.gov/). Sequence types (ST) and allele numbers were 
determined with the S. aureus MLST website (http://saureus.mlst.net) using sequences 
obtained from 454 sequencing.  
The draft genome of E. meningoseptica ATCC 13253T was sequenced using the 
Roche 454 GS Junior pyrosequencing platform according to manufacturer’s instructions 
at Oklahoma State University.  Sequencing of ATCC 13253T produced 223,447 reads 
(29.7 X coverage, average read length = 504.9 bp) that were assembled with Roche GS 
de novo assembler (v 2.7).  All draft genomes were then uploaded into the Rapid 





2.7 Pulsed-field gel electrophoresis (PFGE) 
 Initially, S. aureus strains were grown overnight in 5 ml of MHB at 37°C (200 
rpm).  The cultures (600 µl) were then transferred to microcentrifuge tubes and harvested 
by centrifugation (16,100 x g, 5 min, 25°C).  The supernatant was then decanted and the 
pellet was resuspended in 400 µl PIV buffer (10 mM Tris-HCl; 1 M NaCl) and vortexed 
gently.  The cells were reharvested (16,100 x g, 5 min, 25°C) and the microcentrifuge 
tubes were blotted to remove excess fluid.  The pellet was resuspended in 200 µl of PIV 
buffer and mixed by pipetting.  Each cell suspension was then diluted 1/200 with PIV 
buffer and the OD600nm was read.  To ensure that all samples have the same cell 
concentration, the OD600nm value was put into the following dilution formula: (OD x 40 x 
210) -210.  A 1.5% low melting point agarose (Sigma Aldrich, St. Louis, MO) solution 
was then made up in 0.5X TBE (50 mM boric acid, 50 mM Tris, 1 mM EDTA) as 
required (150 µl of the agarose is required for each strain investigated).  The solution was 
microwaved until the agarose dissolved and was then equilibrated in a 60°C water bath 
for 5 min.  In a microcentrifuge tube at 60°C, initially 150 µl of the 60°C agarose and 150 
µl of cells are added and then mixed via vortexing.  Twenty five microliters of this cell 
suspension is then pipetted onto a flat parafilmed slide surface and covered with another 
parafilmed slide with 1 mm spacers and the disks are frozen at -20°C for 10 min.  The 
lysis solution was prepared by adding 1 ml of EC buffer (1 M NaCl, 6 mM Tris-HCl; pH 
8.0, 100 mM EDTA, 0.2% sodium deoxycholate, 0.5% sarkosyl), plus 2 mg/ml of 
lysozyme (Sigma Aldrich) powder and 8 µl of lysostaphin (Sigma Aldrich; 10 mg/ml 
stock) per strain to a microcentrifuge tube.  All the disks from a single strain were then 
placed in 1 ml lysis solution in a microcentrifuge tube and allowed to lyse for 3 h at 
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37°C.  After lysing, the tubes were placed on ice for 10 min. to firm the disks.  The lysis 
buffer was then removed by pipetting and 1 ml of ES buffer (500 mM EDTA, 1% 
sarkosyl) and 10 µl of Proteinase K (Sigma Aldrich; 10 mg/ml stock) was added per 
strain and the samples were left overnight in a 50°C water bath.  The next day, the 
samples were placed on ice for 10 min. and the buffer was removed and the disks were 
washed in TE buffer (10 mM Tris-HCl, pH 7.6; 1 mM EDTA) at 37°C for 1 h.  This was 
step was repeated five times with the last rinse being overnight for the total removal of 
the protease.  At this stage the disks can be stored at 4°C indefinitely.  The disks were 
placed on ice for 15 min prior to digestion.  For each disk, 50 µl of restriction buffer 
(Buffer 4, New England Biolabs) was prepared for equilibration and 50 µl for digestion 
for a total of 100 µl per strain.  Remove one disk and place into a tube containing 50 µl of 
restriction buffer and the disk was equilibrated for 30 min at 25°C (recommended 
temperature for the SmaI enzyme).  The restriction mix was prepared by adding 1.2 µl of 
SmaI enzyme per strain to 50 µl of the diluted buffer 4 mix.  The equilibration buffer was 
removed from the tubes containing the disks and the 50 µl of restriction mix was added 
and the tubes then sat overnight at 25°C.  The pulsed field gel was a 1% agarose (BioRad, 
Hercules, CA) made in 0.5X TBE (45 mM Tris; 45 mM Boric acid; 1 mM EDTA, pH 
8.0) and the running was also 0.5X TBE which was cooled in the pulsed field unit to 4°C 
approximated 30-40 min before loading the digested agarose disks.  The disks were 
placed on wet ice for 10 min prior to loading the gel.  Using a spatula, the disks were 
loaded against the bottom part of the well and once all disks were loaded, each well was 
sealed with 1.5% agarose.  The gel was placed in the unit and the running conditions (6 
volts/cm, initial switch time of 1 s, final switch time of 30 s, temperature of 11.3°C, and a 
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total run time of 23 h) were set.  Once the gel was run, it was stained with ethidium 
bromide for 45 min and then washed with double distilled water for another 45 min.  The 
image of the ethidium-stained SmaI bands was captured using the BioRad Gel Doc 
program and analyzed visually. 
2.8 Antibiotic susceptibility testing 
2.8.1 Kirby-Bauer disk diffusion 
The antimicrobial susceptibility was determined by the Kirby-Bauer disk 
diffusion method according to the CLSI (76).  A single colony of each isolate was 
inoculated into 2 ml of MHB and incubated overnight at 30°C (Elizabethkingia strains) or 
37°C (S. aureus strains), 200 rpm.  Cultures were diluted to an OD625nm of 0.1 in fresh 
MHB.  Each adjusted suspension was then streaked onto MHA plates using a sterile 
cotton swab and antibiotic disks (Remel, Lenexa, KS) were put onto the bacterial lawn 
and incubated at appropriate temperature for 24 h.  Zones of inhibition were then 
measured in mm. 
2.8.2 Gradient plate analysis 
 Gradient plate analyses were performed as described previously (151).  Briefly, 
gradient plates were prepared by pouring 40 ml of MHA into a 90 mm x 90 mm square 
petri dish raised at one side by a 1 ml pipette (6 mm) and left to dry overnight.  After 24 
h, 40 ml of MHA containing the correct antimicrobial concentration was then poured on 
top of the drug-free layer and allowed to solidify for 3 h at room temperature.  Overnight 
MHB cultures grown at 37°C (S. aureus strains) or 30°C (Elizabethkingia strains), 200 
22	  
	  
rpm, were diluted in fresh MHB to an OD625nm of 1.0.  The resulting diluted cultures were 
used to streak the gradient plates three times (using a sterile cotton swab) for each row, in 
a concentration dependent manner (low concentration to high concentration).  Plates were 
incubated for 48 h (37°C or 30°C) and distance of confluent growth along the gradient 
was measured and recorded in mm.     
2.8.3 Vancomycin E-test  
 Vancomycin E-tests were performed as described by the manufacturer’s 
instructions (AB Biodisk, New Jersey).  Overnight S. aureus MHB cultures (37°C, 200 
rpm) were diluted to an OD600nm of 0.25.   A cotton swab, dipped into the diluted cultures, 
was then used to spread an even inoculum onto MHA plates containing 2% NaCl.  The 
plates were allowed to dry for 15 min and a single vancomycin E-test strip was placed in 
the center of the plate with tweezers flamed in 95% ethanol.  After 24 h incubation 
(37°C), the MIC was read at the concentration at which growth was inhibited per 
manufacturer’s instructions. 
2.9 Vancomycin growth curves 
 Duplicate cultures (250 ml) were initiated with a 2 % (v/v) inoculum from LB 
overnights of MM66 and MM66RVI-4 (37°C, 200 rpm).  Cultures were grown to an 
OD580nm of 0.4 and then vancomycin was added (2.5 µg/ml final concentration) to one 
flask per strain.  Sterile water was added to the second flasks as the control.  Cultures 




2.10 Vancomycin population analysis 
 Vancomycin population analyses were performed as previously described with 
slight modifications (151).  Overnight MHB cultures of S. aureus strains MM66 and 
MM66RVI-4 (37°C, 200 rpm) were adjusted to an OD580nm of 1.0 in fresh MHB and then 
serially diluted to 10-6.  A 10 µl aliquot of each dilution was inoculated onto MHA plates 
containing increasing concentrations of vancomycin (0 to 2.7 µg/ml).  Following 
overnight incubation at 37°C, colony counts were then determined on plates containing 
dilution spots with 10 to 50 colonies. 
2.11 Sequence analysis and phylogenetic tree construction 
 Sequence homology comparisons were done utilizing sequences within the 
GenBank databases using the BLAST (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) and 
RAST programs (6). Nucleotide and protein sequence alignments and respective percent 
identities were produced using MacVector (v 12.6.0). Multiple sequence alignments for 
construction of the phylogenetic trees were completed using the Molecular Evolutionary 
Genetics Analysis (MEGA v5.2.1) software (182). The models used for the evolutionary 
distances were determined by MEGA (182).  
In total, 59 partial 16S rRNA gene sequences (> 1000 bp) were obtained from the 
NCBI databases (http://www.ncbi.nlm.nih.gov/pubmed/).  Alignment of the sequences 
was performed using the MUSCLE algorithm and trimmed to equal lengths (1287 bp). 
The evolutionary distances (phylogenetic tree) were computed using the Kimura 2-
parameter method (Kimura, 1980) and Flavobacterium johnsoniae UW101 was used as 
an outlier.   
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 Protein sequences of RpoB, GyrB, GroEL were obtained from the NCBI 
databases for 19 species of the Chryseobacterium, Flavobacterium, Riemerella and 
Elizabethkingia genera.  Alignments were first performed for each protein individually 
and the resulting alignments were trimmed to equal lengths (GyrB, 228 amino acids (aa); 
RpoB, 249 aa; GroEL, 131 aa).  The final trimmed protein sequences were combined 
end-to-end (GyrB, RpoB, GroEL; total size: 608 aa) for each species to obtain one 
concatenated protein sequence.  A MUSCLE alignment was performed using the 
concatenated protein sequences and then used for construction of the phylogenetic tree.  
The evolutionary distances were computed using the Jones-Taylor-Thornton model (84). 
 Fourteen different protein sequences of previously characterized RND transporter 
genes were obtained from the NCBI databases and aligned to the 5 RND transporter 
sequences from E. meningoseptica ATCC 13253T. Alignment of the proteins was 
performed using the MUSCLE algorithm and used for construction of the phylogenetic 







RESULTS AND DISCUSSION 
 
 
3.1 Isolation and characterization of S. aureus strains from a Paso Del Norte dairy 
Growth on Baird Parker and mannitol salt agar, Gram stain and catalase reaction 
presumptively identified 40 S. aureus isolates from 29 milk samples.  More than one 
isolated colony was chosen from samples that showed variable reactions on the selective 
media above (designated by strain number followed by a, b, or c).  All 40 of these isolates 
were coagulase and nucA positive. These isolates included 7 from hospital cows (H 
strains), 18 from parlor A cows (PA strains) and 15 from parlor B cows (PB strains).  
None of the strains investigated demonstrated resistance to vancomycin by disk diffusion. 
All H strains except H15c were oxacillin-resistant, yet all 7 H strains were mecA positive. 
One H strain (H30) also demonstrated erythromycin resistance, while 3 H strains (H24, 
H26a, H26b) demonstrated resistance to ciprofloxacin and erythromycin. Strain H29 
demonstrated resistance to both of these antimicrobials, as well as tetracycline and 
imipenem, and inducible clindamycin resistance. None of the PA and PB strains were
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methicillin-resistant or mecA-positive. PA18 however demonstrated ciprofloxacin and 
erythromycin resistance, while PB26b demonstrated resistance to fusidic acid.  
Contamination of milk by S. aureus has been previously linked to staphylococcal 
food-borne outbreaks (5, 46, 135). Studies have also revealed that virulence of S. aureus 
is significantly increased when grown in milk whey compared to growth in TSB (120). In 
addition, mastitis isolates have also demonstrated the ability to resist phagocytosis by 
bovine cells when grown in the presence of milk (180). A representative milk and TSB 
growth curve was produced to examine the ability of select dairy isolates (H29, H15a and 
PB32) and a common S. aureus laboratory strain (COL) to grow in commercially 
available milk compared to standard laboratory media (Figure 2). Both COL and H29 
produced similar numbers of CFU/ml in milk as they did in TSB, however COL 
produced fewer CFU/ml in milk compared to H29 (Figure 2). Strains H15a and PB32 
exhibited a decrease in CFU/ml when grown in milk compared to growth in TSB and 
both strains demonstrated differences in the levels of growth when compared to COL and 
H29 (Figure 2). All strains investigated demonstrated the ability to grow in milk and 
suggests the ability of these strains to be a source of staphylococcal food-borne 








Figure 2. Representative growth curves for four Staphylococcus aureus strains (COL, H29, 
H15a and PB32) grown in milk and tryptic soy broth (TSB). 
 
PFGE of SmaI-digested DNA separated the 40 strains into multiple pulsed-field 
types (PFT).  PFT-A was the most frequently isolated PFT, representing 37.5% (n = 15) 
of all isolates (Figure 3). PFT-B contained the largest number of H strains (n = 5) and 
PA18, all of which demonstrated resistance to two or more of the antimicrobials 
investigated.  PFT-C, -D and -E all contained two or more strains isolated from a single 
milk sample, which indicates the clonality of the colonies isolated from these milk 








































one milk sample (PA8a and PA8b; PA10a and PA10b), PFGE analysis revealed that the 
SmaI restriction fragment length polymorphisms were different (Figure 3).  Both PA8b 
and PA10b clustered within the PFT-A strains, while PA8a and PA10a clustered close to 
PFT-A strains (Figure 3). This suggests that more than one S. aureus clone was present in 
each of these milk samples.  
We next chose two strains for 454 sequencing. One was H29 which was a 
representative of the most widely distributed MRSA clone (PFT-B) and the other was 
PB32, which was a MSSA clone from PFT-C, that was most related to the PFT-B MRSA 
clones identified in this study. 
The draft genome of MRSA strain H29 derived from 119 contigs (all >200 bp in 
length), consists of 2,844,315 bp, which encodes for 2,664 protein-coding genes.  MLST 
revealed that strain H29 is ST5 (1,4,1,4,12,1,10), a sequence type that contains human 
MRSA isolates and is found within CC5. The presence of ST5 MRSA strains circulating 
in Paso Del Norte area hospitals located near the dairy investigated has previously been 
reported on (38, 141).  
Overall, the H29 draft genome (accession no. PRJNA179361) proved to be 100% 
identical over 97% of the human MRSA strain JH1 genome (accession no. NC009632) 
by BLASTn comparisons. S. aureus JH1 is also an ST5 strain that was isolated from a 
patient with endocarditis and the JH lineage is capable of developing intermediate 
resistance to vancomycin (136, 170). A vancomycin E-test demonstrated that H29 does 




Figure 3. Pulsed-field gel electrophoresis (PFGE) patterns of SmaI-digested    
chromosomal DNA of Staphylococcus aureus strains investigated and dendrogram of 



























































































































































































































Contig 1 (27,139 bp) of the H29 draft genome represents a β-lactamase plasmid 
that had only 42% nucleotide similarity to plasmid pSJH101 (accession no. NC009619) 
found in JH1; yet was 99.5% identical to plasmid SAP048A (27,268 bp; accession no. 
GQ900406) found in S. aureus strain NE 3809, a human clinical blood isolate from 
Nebraska. SAP048A is a representative of pIB485-like plasmids that carry ΔTn552 
encoding β-lactamase and a cluster of staphylococcal enterotoxin genes (sed, sej, and ser) 
that have contributed to outbreaks of S. aureus food-born illness (for review see 
Gustafson and Wilkinson, 2005; Shearer et al., 2011). In addition, contig 34 of H29 
demonstrated 97% nucleotide identity to a previously described enterotoxin gene cluster 
(egc) operon that encodes five enterotoxin genes, seo, sem, sei, sen, seg and two 
pseudogenes, ϕent1 and ϕent2, located on the νSaβ genomic island (82, 99). The H29 
draft genome also contains the SCCmec sequence type II which harbors a erythromycin 
resistance gene (erm) (77), a Tn916-like transposon containing the tetracycline resistance 
gene tetM (36), and a mutation in the DNA gyrase gene (gyrA) that leads to a 84S!84L 
alteration in GyrA that has previously been tied to ciprofloxacin resistance (161).  
The draft genome of MSSA strain PB32 (accession no. PRJNA179544) derived 
from 80 contigs consists of 2,808,519 bp which encodes 2,632 protein-coding genes.  
MLST sequences derived from the draft genome confirmed PB32 as a ST124 
(3,1,1,37,1,5,3) strain of CC97, which is represented by bovine as well as shared 
bovine/human strains (175). There does not appear to be any readily identifiable plasmid 
sequences in the PB32 draft genome. 
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Overall, the PB32 draft genome (accession no. PRJNA179544) proved to be 
100% identical over 94% of the human MRSA strain 04-02981 genome (accession no. 
CP001844.2) by BLASTn comparisons. Strain 04-02981 is a plasmid-less ST225 
(1,4,1,4,12,25,10) multidrug-resistant SCCmec sequence type II strain that was isolated in 
Köln in 2004. (140). The ST225 sequence type first described in the 1990s in the USA 
represents a single locus variant of ST5 strains and the genome of 04-02981 is also co-
linear with the JH1 genome (140).  
S. aureus SCCmec insertion is carried out by site-specific recombination between 
the attB site on the chromosome and the attS site on SCCmec (78, 88).  This 
recombination event results in copies of the att sites at each end of SCCmec, with attR 
within orfX and attL at the other end of the SCCmec (194). A 27,082 bp segment within 
contig 15 (215,480 bp) contains several genes previously described in SCCmec elements 
as well as the attL attachment site (Figure 4). These genes include the recombinase genes 
ccrA and ccrB, pbp4, and an arsenic resistance operon (arsA-D, arsR). It has been 
reported that all ST225 and JH strains carry the same ccrB gene (140). The ccrB gene of 
PB32 however only demonstrated 93% nucleotide identity to the ccrB of the ST225 strain 
04-02981 and 39% nucleotide identity to the ccrB of the JH1 strain. mecA and mecA 
controlling genes (mecI and mecRI) were not present in the draft genome of PB32. In the 
PB32 draft genome, orfX is found on one end of contig 75 (130,864 bp) as well as the 
attR attachment site (Figure 4) suggesting that contig 15 and contig 75 belong together. S. 
aureus strains that possess chromosomally-located remnants of SCCmec determinants, 
including some with a pbp4 gene, have been reported on (27, 42, 109, 116, 169, 200) and 
































































































































































































































































































SCCmec remnant. It is of interest to note that like PB32, ST225 MSSA isolates can also 
carry SCCmec remnants (140). 
PB32 contains another mobile genetic element, a novel bovine staphylococcal 
pathogenicity island (SaPIbov) located within contig 66 (127,041 bp) which will be 
referred to as SaPIbovPB32. Sequence comparison of SaPIbovPB32 (nt 90,549 – 
104,940) with other SaPIbov sequences, demonstrated the greatest nucleotide identity to 
SaPIbov5 (accession no. HM228919) at 79% identity followed by 66% identity to 
SaPIbov4 (accession no. HM211303) (191). SaPIbov5 (13,526 bp) was described in a S. 
aureus ST398 clone (191). Staph. aureus strains that contain SaPIbov5 have been 
isolated from different animals including cows, sheep and goats (191).  SaPIbovPB32 is 
14,391 kb in length and is flanked by 21 bp direct repeats that are found in other SaPIbov 
sequences (Figure 5). Of the 18 open reading frames (ORF) found in SaPIbov5, 11 were 
shared with SaPIbovPB32, which included the integrase, excisionase, primase-like genes 
as well as a von Willebrand factor-binding gene (vwb). PB32 also has a second vwb 
variant located on contig 12. Like PB32, it has been previously been reported that 
ruminant-associated S. aureus strains possess two variants of vwb, one located on 
SaPIbov and another located elsewhere on the chromosome (58, 191). The vwb gene 
contained within the SaPIbov is responsible for coagulation of ruminant-specific plasma 
and is suggested to play an important role in host-adaptation (58, 191). The genome of 
strain 04-02981 does not demonstrate the presence of a SaPIBov sequence. Lastly, a gene 
encoding enterotoxin A (sea) that produces a product with 91% amino acid identity to the 












































































































































































































































































































PFGE analysis revealed clonally-related S. aureus strains circulating within the dairy 
herd investigated. Strains represented by PFT-A, which included 13 MSSA strains and 
two mecA-positive strains (H15a and H15c), were the most widely distributed clones 
found within this herd. The presence of mecA-positive strains within PFT-A, including 
one that was also oxacillin-resistant (H15a), suggests that a PFT-A clone has either 
gained or lost the mecA determinant. Collectively, genomic analysis corroborates the 
multidrug resistance phenotype displayed by H29 and revealed the presence of both a 
novel SaPIbov sequence and SCCmec remnant in PB32. Genome analysis also 
demonstrated that H29 carried enterotoxin genes on both plasmid and chromosome 
locations, while PB32 harbored a chromosomally-located sea gene. This finding suggests 
that these strains are capable of causing staphylococcal food-poisoning. In addition, while 
the draft genome of PB32 was most related to MRSA strain 04-02981, based on 
differences in SCCmec and SaPIbov content, ST sequence types and ccrB sequences, 
PB32 and 04-02981 represent clearly diverged clones. Overall, our data demonstrates that 
H29 and PB32 represent novel clones of human and/or bovine-related strains of S. 
aureus. We speculate that the unique genomic features of these strains possibly reflect the 






3.2 Draft genomes of heterogeneous vancomycin-intermediate Staphylococcus 
aureus strain MM66 and MM66 variant exhibiting increased vancomycin 
susceptibility 
3.2.1 Characterization of vancomycin resistance levels of MM66 and  MM66RVI-4 
 Vancomycin is currently the antibiotic of choice for treating serious MRSA 
infections (103, 111) and resistance can now be found globally. Previously, a clinical 
hVISA strain MM66 was isolated from the Memorial Medical Center in Las Cruces, New 
Mexico (38). S. aureus strain MM66RVI-4 was obtained by passaging MM66 through 
drug-free media and selecting for MM66 colonies via replica plating that did not grow on 
plates containing 1 µg/ml of vancomycin. In order to determine the differences in 
vancomycin susceptibility between MM66 and MM66RVI-4, vancomycin E-test strips 
and vancomycin gradient plates were utilized.  It was determined that the hVISA parent 
strain MM66 exhibits a vancomycin E-test MIC of 3 µg/ml while the vancomycin MIC 
of MM66RVI-4 was slightly decreased (2 µg/ml) in comparison to MM66 (Table 1). 
MM66RVI-4 demonstrated a significant decrease in the distance grown on a 0 → 3 µg/ml 
vancomycin gradient compared to MM66 (Table 1). Teicoplanin, another glycopeptide 
antibiotic, was used to determine whether the increase in susceptibility seen with 
MM66RVI-4 was unique to vancomycin or if it can be seen with other glycopeptide 
antibiotics.  Teicoplanin gradient plates (0 → 3 µg/ml) of MM66RVI-4 demonstrated a 
similar increase in susceptibility to teicoplanin as vancomcyin, demonstrating that 
selection of MM66RVI-4 for increased susceptibility to vancomycin also confers 
increased susceptibility to other glycopeptide antibiotics (Table 1). It has been previously 
shown that selection for the VISA phenotype in the laboratory can also lead to the loss of 
SCCmec or demonstrate decreased levels of methicillin-resistance (1, 11, 139). Oxacillin 
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(methicillin) gradient plates were used to determine if there were differences in 
methicillin resistance levels upon selection of increased vancomycin susceptibility in 
MM66RVI-4.  MM66RVI-4 demonstrated a significant decrease in methicillin resistance 
compared to MM66, as seen with the gradient plate technique (Table 1). This infers the 
possibility of either loss of the mecA gene responsible for methicillin resistance, or 
mutations within the mecA coding region leading to loss of function or decreased 
transcription of mecA.  To determine if MM66RVI-4 lost the mecA gene, PCR was 
performed to amplify a 286 bp region of mecA from both MM66 and MM66RVI-4.  
Amplified MM66 DNA demonstrated a single 286 bp band while the DNA of 
MM66RVI-4 did not produce a mecA amplicon, confirming loss of the mecA gene and 









Strain   Vancomycin   Vancomycin     Teicoplanin      Oxacillin 
  E-test (µg/ml)      Gradient        Gradient       Gradient 
MM66 3 
0 → 3 µg/ml 0 → 3 µg/ml 0 → 175 µg/ml 
61.6 ± 4 30.6 ± 4 84.0 ± 2 
MM66RVI-4 2 
0 → 3 µg/ml 0 → 3 µg/ml 0 → 0.5 µg/ml 
41.6 ± 3* 16.0 ± 3* 73.0 ± 5 
Numbers for gradient plates represent distances grown (mm) on 90 mm square petri plates with standard deviations (n=3) 
*Denotes: MM66RVI-4 compared to MM66, p-value ≤ 0.05 
Table 1. Antibiotic susceptibilities using gradient plates and vancomycin E-test  
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A method that can be used to measure increased resistance to antimicrobials is 
bacterial growth curves in the presence of a specific antimicrobial.  Growth of MM66 and 
MM66RVI-4 with and without the presence of 2.5 µg/ml vancomycin was measured by 
monitoring the optical density for an 8 h period.  Without the presence of vancomycin, 
both MM66 and MM66RVI-4 exhibited similar growth.  In the presence of 2.5 µg/ml 
vancomycin, MM66RVI-4 demonstrated a slight decrease in growth compared to MM66.  
As previously stated, hVISA are strains that have a subpopulation of cells resistant to 
vancomycin and are not detectable by standard broth and disk diffusion techniques. 
Therefore, vancomycin population analyses were then performed in an effort to 
determine if any minor differences in vancomycin resistance could be seen between the 
two strains. Differences in the number of surviving cells at various vancomycin 
concentrations were observed. It is important to note that at vancomycin concentrations 
of 1.5 µg/ml to 2.5 µg/ml, MM66RVI-4 was still able to produce colonies but not to the 
extent of the parent MM66 (Figure 6).  This suggests that while MM66RVI-4 expresses 
an increased vancomycin susceptibility compared to MM66 utilizing vancomycin E-tests 
and gradient plates, it did not lose the ability to express some level of vancomycin 







Figure 6. Vancomycin resistance population analysis profile of Staphylococcus 
aureus strains MM66 and MM66RVI-4. 
 
 
3.2.2 MM66 and MM66RVI-4 draft genome analysis 
 In an effort to determine the genetic alterations, if any, that may be attributed to 
the phenotypic changes seen in MM66RVI-4 compared to MM66, in addition to genes 
involved with the hVISA mechanism, whole-genome sequencing was utilized. The 
MM66 draft genome sequence was 2,834,320 bp in length (32.9% G+C content) and 
included 2,684 protein-coding regions distributed in 114 contigs (>200 bp). The 
MM66RVI-4 draft genome sequence was 2,732,996 bp in length (33% G+C content) and 
included 2,563 protein-coding regions distributed in 197 contigs (>200 bp).  MLST 
analysis of the drafts genomes demonstrated that both MM66 and MM66RVI-4 were 

































presence of ST 5 MRSA strains circulating among dairies in the Paso Del Norte area has 
previously been reported on (122, 141) and could suggest the clonal spread of these 
strains.  
 Initially, PCR confirmed deletion of mecA from MM66RVI-4, corroborating the 
loss of methicillin-resistance seen in this strain. However, further analysis of the MM66 
and MM66RVI-4 draft genomes revealed that the majority (~46 kb) of the SCCmecII that 
is found in MM66 (~49 kb) was missing in MM66RVI-4 (Figure 7).  It has been 
previously found that the passaging of MRSA strains through drug-free media can result 
in the spontaneous loss of methicillin-resistance (57, 67). Therefore, not only can 
selection for the VISA phenotype result in the loss of SCCmec, but selection for strains 
with increased susceptibility to vancomycin can as well.  It has been argued that the loss 
of mecA is advantageous to the VISA mechanism (139) however, what role, if any, the 
loss of mecA plays in the selection for increased susceptibility to vancomycin requires 
further investigation. 
It has been suggested that the VISA phenotype of S. aureus is the result of an 
accumulation of mutations over time or in some cases, a single mutation (22, 72, 136, 
168). Mutations associated with the hVISA/VISA phenotype have been identified within 
a variety of S. aureus genes [for review see (70)]. Utilizing the draft genomes of MM66 
and MM66RVI-4, sequence based comparisons with known hVISA/VISA genes were 
performed in an effort to determine which, if any, of these mutations are found in MM66 
and MM66RVI-4.  MM66 and MM66RVI-4 nucleotide/protein sequence comparisons 
























































































































































































































































































No mutations in known genes responsible for the hVISA/VISA phenotype (rpoB, walKR, 
vraR, graR, isdE, yycH) were found within the MM66 and MM66RVI-4 draft genomes. 
This suggests that while these genes may be important for the VISA mechanism found in 
other VISA strains, they do not play a role in the hVISA phenotype exhibited by MM66 
and MM66RVI-4.  
The GraRS two-component regulatory system has been shown to control the 
expression of many genes (63) as well as playing a role in the VISA mechanism (32, 40, 
74). For example, a single amino acid change in GraS (T136I) has been shown to 
contribute to the VISA phenotype of a clinical VISA strain (JKD6008) compared to a 
vancomycin-susceptible S. aureus (VSSA) strain (JKD6009) from the same patient (74). 
Introduction of the GraS T136I mutation into the VSSA strain JKD6009 demonstrated 
increased vancomycin resistance but not to the extent of the full VISA strain JKD6008 
via population analyses (74). In this study, the GraS mutation was found to significantly 
contribute to the VISA phenotype, however, it was not the only mutation found and 
suggested that other mutations in addition to GraS may play a role in the VISA 
phenotype of these strains (74). Interestingly, a single mutation was also found within 
graS of both the MM66 and MM66RVI-4 draft genomes. Both MM66 and MM66RVI-4 
harbored a novel mutation in graS, resulting in an amino acid change of S270N. PCR and 
Sanger sequencing were used to confirm the graS mutation found in MM66 and 
MM66RVI-4. Results from the vancomycin growth curves and population analysis 
assays demonstrated only minor phenotypic differences between MM66 and MM66RVI-
4 in the presence of vancomycin. It can therefore be hypothesized that this graS mutation 
may contribute to the hVISA phenotype of MM66 and since the mutation is found in both 
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strains, may account for the similar levels of vancomycin resistance exhibited by 
MM66RVI-4. 
In an effort to determine the genetic changes that may be associated with the 
minor increase in vancomycin susceptibility exhibited by MM66RVI-4, both draft 
genomes were aligned to identify single nucleotide polymorphisms (SNP) and/or 
insertions/deletions between the two strains. Alignment of the draft genomes produced a 
total of 9 nucleotide differences between MM66 and MM66RVI-4 (Table 2). Due to the 
fact that mutations linked to the hVISA/VISA phenotype have been found within cell 
wall-related genes, it is of no surprise that 5 of the alterations in MM66RVI-4 are found 
within genes known to be associated with the cell wall. It is of particular importance to 
point out the multiple changes found within the vraG gene of MM66RVI-4, which 
encodes an ATP-binding cassette (ABC) transporter permease and results in a premature 
stop codon at the 440th amino acid position (out of 629 amino acids). vraG is upregulated 
in the VISA phenotype however mutations within vraG have been shown to be 
responsible for increased vancomycin susceptibility in two different MRSA and VISA 
strain backgrounds (127). Based upon the mutations found within vraG it could be 
hypothesized that these mutations are responsible for the increased vancomycin 
susceptibility exhibited by MM66RVI-4 (MIC = 2 µg/ml) compared to MM66 (MIC = 3 
µg/ml). Interestingly, vraG expression is under the control of graRS (127) and both 
MM66 and MM66RVI-4 contain a mutation within graS. We also hypothesize that the 
effects of the graS mutation on vraG expression or VraG activity might contribute to the 
vancomcyin-intermediate mechanism of MM66. Therefore, the mutations in vraG in 
MM66RVI-4 may reduce the effects of the vancomycin-intermediate supportive graS 
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mutation on vraG expression or VraG activity, and the vraG mutations in MM66RVI-4 
may contribute to the reduced expression of the vancomycin-intermediate mechanism in 
this strain. It can also be postulated that the other genetic alterations found within 
MM66RVI-4 (Table 2) play a role in the increased vancomycin susceptibility of 
MM66RVI-4 as well. However, it should be noted that with the exception of the 
mutations found within vraG, the majority of these differences between MM66 and 
MM66RVI-4 are found within homopolymer regions of these genes. It has been 
previously found that homopolymer regions are known to be a source of sequencing 
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3.2.3 Conclusions and future directions 
 In this study, we were able to isolate MM66RVI-4, a MM66 clone that 
demonstrated increased susceptibility to vancomycin. MM66RVI-4 was able to 
demonstrate slightly reduced growth and a reduced ability to produce cells that survive 
on inhibitory concentrations of vancomycin.  MM66RVI-4 also demonstrated an almost 
complete loss of the SCCmecII, corroborating the decrease in methicillin resistance of 
this strain. Investigations into the genetic differences between MM66 and MM66RVI-4 
revealed mutations within genes previously associated with both the VISA phenotype and 
VISA reversion. The GraS mutation may account for the similar levels of vancomycin 
resistance exhibited by MM66 and MM66RVI-4 and that the mutations within vraG of 
MM66RVI-4 may be responsible for the slight increase in susceptibility to vancomycin. 
However, to confirm the significance of these mutations, re-sequencing and confirmation 
is needed to ascertain their role, if any, in the increased vancomycin susceptibility 









3.3 Draft genome sequence of Elizabethkingia meningoseptica 
3.3.1 Antimicrobial resistance mechanisms of Elizabethkingia meningoseptica 
Bacteria have evolved several ways to overcome susceptibility to antibiotics 
which include alteration of drug targets, changes in membrane permeability, inactivation 
of drugs by degradation/modification and drug efflux from cells (148).  In essence, all 
antimicrobial resistance mechanisms prevent the drug from binding to its target.  Not 
much is known about the antimicrobial resistance mechanisms of Elizabethkingia, even 
though the organisms demonstrate a multidrug-resistant (MDR) phenotype (17, 92, 181).  
Utilizing the Kirby-Bauer disk diffusion method we have determined that E. 
meningoseptica strain ATCC 13253T demonstrates resistance to 19 of 30 antibiotics 
tested confirming the MDR phenotype previously seen for this strain (Table 3) (17, 92).  
This strain is resistant to antibiotics representing the following antibiotic classes: 
aminoglycosides, cephalosporins, β-lactams, tetracyclines, lincosamides, streptogramin, 
oxazolidonone, and glycylcycline.  To date, the antimicrobial regimens used for treating 
infections caused by supposed E. meningoseptica are quite variable (93).  This variability 
might also be indicative of the inability of the attending physician to pick the best 
antimicrobial therapy because the species and their antimicrobial susceptibility profiles 
are undefined by the Clinical Laboratory Standards Institute (177).  Due to the variability 
in antimicrobial susceptibility patterns seen amongst Elizabethkingia strains and 16S 
rRNA sequencing not effectively distinguishing between Elizabethkingia species, lead us 
to complete and compare the draft genomes of these organisms.  Analysis of these draft 
genome sequences will provide a firm beginning to the process of correctly establishing 
the species of this genus, in addition, aiding in the identification of possible resistance 
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mechanisms responsible for the MDR phenotype of these organisms.  Whole-genome 
sequencing of E. meningoseptica ATCC 13253T produced a draft genome that was 
3,797,222 bp (35.2% GC content) in length and included 3,486 protein-coding regions 














Table 3.  Antibiotic susceptibility profile for E. meningoseptica ATCC 13253T 































 Abbreviations: R, resistant; S, susceptible; I, intermediate-resistance 
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The β-lactam class of antibiotics is often the first antimicrobial choice for the 
treatment of infections caused by Gram-negative bacteria (98). To date, the only 
mechanism of antibiotic resistance studied in the Elizabethkingia species revolves around 
its resistance to β-lactam antibiotics (7, 132, 158, 159, 201).  The expression of β-lactam 
and related drug resistance by Elizabethkingia is attributed to the presence of at least 
three chromosomally located β-lactamase genes. This includes two different metallo-β-
lactamase (MβL) genes (blaB and blaGOB) and one extended-spectrum β-lactamase gene 
(ESBL; blaACME) (8, 9, 159). These genes produce enzymes that hydrolyze the β-lactam 
ring found in β-lactam antibiotics and related antimicrobials, therefore inactivating these 
drugs.   
Metallo-β-lactamases belong to the Class B/Group 3 of the Amber/Bush-Jacoby-
Medeiros classification on the basis of their functional properties (3, 19).  Three 
subclasses (B1, B2, B3) for MβLs have been described and are based on sequence 
similarities between these enzymes (49). The first MβL found in Elizabethkingia, blaB, 
encodes a 249 amino acid polypeptide and is a Class B MβL that belongs to the Subclass 
B1 (159).  Protein sequence comparison to other MβLs indicates blaB shares the greatest 
homology to the MβL enzymes Bc-II from Bacillus cereus (35% amino acid identity) and 
CcrA from Bacteroides fragilis (27% amino acid identity) (159).  The second MβL gene 
found in Elizabethkingia species, blaGOB, encodes a 290 amino acid polypeptide and is 
also a Class B MβL but belongs to the Subclass B3 (7).  Protein sequence comparison 
indicates blaGOB shares the greatest homology to FEZ-1 from Legionella gromanii (42% 
amino identity) and L1 from Stenotrophomonas maltophilia (18% amino acid identity) 
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(7, 69). The substrate profiles for both blaB and blaGOB have been shown to be broad, 
with the ability to hydrolyze the penicillin, cephalosporin, and carbapenem classes of β-
lactam antibiotics (7, 53, 159, 190, 201).  Alignment of the protein sequences of blaB and 
blaGOB confirms the two MβL genes found in Elizabethkingia are different as they only 
share 11% amino acid identity (7). The third β-lactamase, blaACME found in 
Elizabethkingia species is a Class A serine β-lactamase within Group 2e of the Bush-
Jacoby-Medeiros classification (3, 19, 158).   The blaACME gene encodes a 295 amino 
acid polypeptide that demonstrates the greatest homology to the Class A enzymes VEB-1 
from Escherichia coli (46% amino acid identity), CblA from Bacteroides uniformis (40% 
amino acid identity) and PER-1 from Pseudomonas aeruginosa (39% amino acid 
identity) (158).  Like the MβLs in Elizabethkingia, the ESBL blaACME also exhibits a 
broad substrate profile, with the ability to hydrolyze cephalosporins, penicillins and 
monobactams (158).  Taken together, the presence of these three chromosomally-located 
β-lactamases enables Elizabethkingia to effectively be resistant to most β-lactam 
antibiotics and emphasizes the difficulty in the treatment of infections caused by these 
organisms.    
The β-lactamases found within Elizabethkingia exhibit heterogeneity adding to 
the complexity of the MDR phenotype.  Two variants of blaACME (9, 158), 13 variants of 
blaB (7, 159, 201, 207) and 18 variants of blaGOB (7, 132, 207) have been reported.  
Woodford et al., (2000), characterized and determined the distribution of the blaB-1 and 
blaACME genes from several reference strains of E. meningoseptica (National Collection 
of Type Culture [NCTC] collection), including the E. meningoseptica type strain ATCC 
13253T (201).  In this study, the blaB-1 gene was only detectable by PCR in 5 of the 15 
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NCTC strains and the blaB-1 gene could not be detected in the type strain (201).  
However, resistance of the type strain to the carbapenem antibiotics, imipenem and 
meropenem, suggested the presence of a novel variant of the blaB-1 carbapenemase 
(blaB-3) (201).  Analysis of the 13 BlaB variant sequences described to date revealed 86 
to 100% amino acid identity (81 to 100% nucleotide identity) amongst each other (Figure 
8).  It should be noted that BlaB-3 and BlaB-4 are in fact the same genes as they 
demonstrate 100% nucleotide and amino acid identity to each other, making the total 
number of Elizabethkingia blaB variants to be 12 (7, 201).  Upon further examination of 
these BlaB variant sequences by our laboratory, ATCC 13253T in fact demonstrates 99% 
amino acid identity not only to BlaB-3 (BlaB-4), but to BlaB-12 and BlaB-13 as well.  In 
this same study, PCR detection for the ESBL blaACME gene, which was found in other 
presumed E. meningoseptica strains, was negative for ATCC 13253T (201).  Utilizing our 
draft genome sequence of ATCC 13253T, the inability to detect blaACME is due to 
sequence differences that are found between strains of E. meningoseptica and that the 
primer sequences used were designed to detect specific β-lactamase sequences.  For 
example, blaACME and blaCME-2 demonstrate 98% amino acid identity to each other while 
the β-lactamase found in ATCC 13253T demonstrates 73% and 74% amino acid identity 
(73% nucleotide identity) to blaACME and blaCME-2, respectively (Figure 9).  This suggests 
the possibility of ATCC 13253T to either possess a novel variant of the blaACME gene or 
that these genes are found within different Elizabethkingia species.  In addition to the 
blaB and blaACME variants, several blaGOB variants have been reported on, demonstrating 
71 to 99% amino acid identity to each other (7, 207).  The first description of blaGOB-1 
was in 2000 from a clinical Elizabethkingia meningoseptica isolate and that same study 
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described E. meningoseptica ATCC 13253T as possessing a GOB-1-like sequence (7).  
However, a MUSCLE alignment of the two protein sequences demonstrates only 80% 
amino acid identity (Figure 10).  More variants have been described since then and the 
ATCC 13253T BlaGOB sequence currently shares 98% and 99% amino acid identity to 
BlaGOB-16 and BlaGOB-17, respectively (207).   
Alignment of all the Elizabethkingia β-lactamase variants described to date 
clearly validates the heterogeneity previously found within these genes.  The difficulty in 
PCR detection of these variants lies in the selection of correct primer sequences due to 
the wide range of nucleotide differences between the genes.  In addition, these variations 
in β-lactamase sequences within this genus could in fact be due to the possession of 


















Figure 8.  Amino acid sequence alignment of the blaB variants from Elizabethkingia 
meningoseptica. The alignment was generated using MUSCLE in MacVector (v 12.6.0).  
The dark gray boxes indicate identical amino acids and the light gray boxes indicate similar 
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Figure 9.  Amino acid sequence alignment of the blaCME variants from Elizabethkingia 
meningoseptica.  The alignment was generated using MUSCLE in MacVector (v 12.6.0). The 
dark gray boxes indicate identical amino acids and the light gray boxes indicate similar amino 
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Figure 10.  Amino acid sequence alignment of the blaGOB variants from Elizabethkingia 
meningoseptica. The alignment was generated using MUSCLE in MacVector (v 12.6.0).  
The dark gray boxes indicate identical amino acids and the light gray boxes indicate similar 
amino acids. Absence of gray indicates different amino acids. Dashes indicate gaps within 
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The susceptibility/resistance patterns of clinical E. meningoseptica isolates have 
been shown to vary substantially (93). Besides the β-lactamase genes described above, 
the bioinformatic analysis of the draft genome of E. meningoseptica ATCC 13253T did 
not reveal the presence of previously characterized horizontally transmitted antimicrobial 
resistance genes. One very important mechanism of “intrinsic” antimicrobial resistance is 
drug efflux, which is mediated by genes that encode single to multiple drug efflux pumps. 
The presence of these genes is in fact required for many acquired (either by mutation or 
gene acquisition) clinical antimicrobial resistance mechanisms. All the bacterial efflux 
pumps described to date fall into one of five groups: resistance-nodulation-division 
family (RND); major facilitator superfamily (MFS); ATP-binding cassette family (ABC); 
small multidrug-resistance family (SMR); and multidrug and toxic compound extrusion 
family (MATE).  In Gram-negative bacteria, RND-type efflux pumps are known to play a 
significant role in resistance to a broad-spectrum of antimicrobial agents including classic 
antimicrobials, detergents, dyes and solvents (138, 147, 199).  RND-type efflux pumps 
were first described in the 1990’s in Escherichia coli (AcrAB-TolC) and Pseudomonas 
aeruginosa (MexAB-OprM) and have been shown to form tripartite membrane 
complexes (117, 149).  These complexes consist of an outer membrane protein (OMP), a 
membrane fusion protein (MFP), and a resistance-nodulation-division transport protein 
(RND) that work together as a proton-drug antiport to pump antimicrobials from the cell 
interior into the external medium.  The presence of intrinsic multidrug efflux pumps, 
particularly of the RND type may play a role in the intrinsic MDR mechanism expressed 
by this organism as they do in other well-characterized pathogens (61, 204, 206).  
Utilizing the ATCC 13253T draft genome, 5 putative efflux gene operons belonging to 
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the RND-type family efflux pumps were identified (123). A phylogenetic analysis of the 
RND-type efflux transporter genes revealed that the transporter genes of E. 
meningoseptica ATCC 13253T form their own clade and diverge away from other well-
characterized Gram-negative RND efflux transporter genes (Figure 11) (61, 125, 129, 
144, 153, 156, 163, 178, 179).   
 
Figure 11. Phylogenetic relationship between representative RND-type efflux transporter 
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Figure 12 shows the alignment of the 5 putative E. meningoseptica RND efflux 
operons (emeABC, emeDEF, emeGHI, emeJKL and emeMNO) compared to the well-
characterized mexAB-oprM operon from P. aeruginosa strain PAO1. Not only are these 
eme operons of similar size to mexAB-oprM, but they also have similar gene 
organization. The percent amino acid identity across the length of the MexAB-OprM 
proteins, were next compared to the Eme protein alignments (Figure 12). Alignment 
results revealed that the Eme proteins demonstrated 24% to 40% amino acid identity to 
the MexAB-OprM from P. aeruginosa.  This data suggests the presence of RND-type 
efflux operons in E. meningoseptica ATCC 13253T.   
 
Figure 12. Organization of the RND-type efflux operons from Elizabethkingia     
meningoseptica ATCC 13253T and amino acid identity to the MexAB-OprM operon 
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One method used to determine if bacteria possess active efflux mechanisms is to 
grow them in the presence of substances known to induce efflux (e.g. salicylate) or 
reduce efflux (e.g. carbonylcyanide m-chlorophenylhydrazone, CCCP) and determine 
their relative resistance levels to various antimicrobials. For example, bacteria grown in 
the presence of salicylate can demonstrate increased resistance to ciprofloxacin, which is 
due to increased expression of efflux pump genes or increased efflux pump activity (10, 
150). Therefore, we examined if the addition of salicylate (1 and 2 mM) to media utilized 
in the gradient plate technique affected the levels of ciprofloxacin (0 → 1 µg/ml gradient) 
resistance of E. meningoseptica ATCC 13253T. No differences in ciprofloxacin 
susceptibility were detected with and without the addition of salicylate as the organism 
grew the entire length of the plate (90 mm) for all concentrations tested. Results of this 
limited induction experiment demonstrated that salicylate addition did not affect 
ciprofloxacin susceptibility levels at the concentrations tested, however salicylate could 
affect the susceptibility levels at different concentrations or with different antimicrobials.  
The Kirby-Bauer disk diffusion assay was also performed on E. meningoseptica ATCC 
13253T with and without the addition of the known efflux pump inhibitor CCCP which 
disrupts the proton motive force (130) required by RND efflux pumps to function. Of the 
7 antimicrobials investigated (tetracycline, cefepime, levofloxacin, ciprofloxacin, 
aztreonam, gentamicin and ceftazidime), 20 µM CCCP addition to the Kirby-Bauer disk 
susceptibility media led to an increase in susceptibility to 2 known RND efflux pump 
substrates, tetracycline and levofloxacin (Figure 13), suggesting that active efflux may be 




Figure 13. Susceptibility of Elizabethkingia meningoseptica ATCC 13253T to tetracycline and 
levofloxacin without (A & C) and with (B & D) the addition of 20 µM CCCP. 
 
 
3.3.2 Potential multi-locus sequence analysis for speciation of Elizabethkingia strains 
  Based on the papers published to date, the vast majority of Elizabethkingia 
strains given a species name is based on 16S rRNA sequencing, which we have already 
brought to question (Figure 1). For example, the 16S rRNA sequences of E. 
meningoseptica ATCC 13253T and E. anophelis R26T demonstrate 98% nucleotide 
identity (87).  Several housekeeping gene sequences from the E. meningoseptica and E. 





effort to identify new genes that can be used for speciation of the Elizabethkingia genus.  
Nucleotide alignment of several highly conserved genes from the E. meningoseptica 
ATCC 13253T draft genome and E. anophelis R26T draft genome (gene and bp identities 
= gln, 86%; gyrB, 87%; recA, 88%; atpD, 92%; dnaK, 92%; groEL, 93%; rpoB, 92%) 
supports previous findings that E. anophelis is at least a separate species and suggests the 
possibility of using these genes for further speciation (87).  With this data, sequencing of 
these conserved genes with slow molecular clocks from new and previously identified 
Elizabethkingia strains may then be utilized to clear up the confusion surrounding the 
speciation of this genus. Figure 14 demonstrates the possibility of using the protein 
sequences of three conserved genes, gyrB, rpoB and groEL, as a means to 
phylogenetically separate the type strains of E. meningoseptica and E. anophelis.  
However, to move the process of characterizing the species within this genus forward, 
more genome sequences and species-specific allele identification of many more strains is 
required.  An additional question that could be asked is whether or not the β-lactamase 
variants and their detection can be utilized for the speciation of this genus based on the 
heterogeneity of these genes?  Comparison of the β-lactamase orthologues from these two 
species revealed 74% to 85% amino acid identity suggesting the possibility of each 
species possessing unique β-lactamases.  However, as seen with the housekeeping genes, 
until the species can be correctly defined, we are unable to demonstrate that these β-
lactamases genes are E. meninogoseptica-specific variants or if these variants are 
composed of multiple Elizabethkingia species.  
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Figure 14. Phylogenetic relationships between representative species of the 
Chryseobacterium, Flavobacterium, Riemerella and Elizabethkingia genera based on 
maximum-likelihood analysis of partial protein sequences of the genes gyrB, rpoB and groEL 
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3.3.3 Conclusions and future directions 
 There are several complications surrounding the speciation of members within the 
Elizabethkingia genus.  The first complication deals with the continued use of 16S rRNA 
sequencing as a means for identifying/naming these species. As established in Figure 1, 
there is not enough differences between the 16S rRNA sequences to accurately name new 
Elizabethkingia isolates and brings us to question the identity of already identified strains 
within this genus. The second complication deals with the variation seen within the three 
β-lactamase genes found within this genus.  Either the heterogeneity seen within these 
genes is truly found within a single Elizabethkingia species or these variants are different 
β-lactamase genes isolated from different Elizabethkingia species.  A third complication 
is the variability with chosen antimicrobial therapies in the treatment of infections caused 
by Elizabethkingia species.  If 16S rRNA sequencing continues to be the standard for the 
identification of Elizabethkingia species, this could lead to a majority of strains being 
misidentified as well as the incorrect antimicrobial therapy being chosen for the treatment 
of these infections. Clarification of the complexities associated with this genus is 
ultimately dependent upon correctly classifying and characterizing the species that 
compose the Elizabethkingia genus. Deciphering the correct species within this genus, as 
well as completing the draft genome sequences, will also provide information to 
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